Evaluation of drotrecogin alpha use in a Belgian university hospital
- 21 Downloads
Sepsis remains a major cause of mortality in ICU patients, despite advances in therapy. Drotrecogin alpha (Drot AA), a recombinant human activated protein C with anti-inflammatory and anticoagulant properties, has proven to be successful in patients with at least one organ failure. Our goal was to evaluate the data in patients with sepsis and at least two organ dysfunctions in a large university hospital in Belgium.
The study was conducted at the medical and surgical intensive care units of the 1850-bed university hospital of Leuven, Belgium.
We retrospectively evaluated the use of Drot AA during a 2.5 year period. At baseline patients’ demographics, type of infection, APACHE II (acute physiology and chronic health evaluation), SOFA (sequential organ failure assessment), DIC (diffuse intravascular coagulation) score and number of organ failures were obtained. Overall hospital mortality was defined as primary outcome measure. Special attention was paid to bleeding, the main side effect of Drot AA.
Main outcome measure
Evalution of hospital and ICU mortality in patients treated with Drot AA for severe sepsis.
Drot AA was administered to 23 patients with sepsis and at least 2 organ dysfunctions; all patients started treatment within 24 h of onset of the second organ failure. Mean age was 59 years. Mean number of organ failures was 3. Overall hospital mortality rate was 47.8%. A 28-day mortality of 26% was found, comparable with the 28-day mortality rate of the PROWESS trial. Bleeding, requiring more than 3 units of blood, occurred in 1 patient. Although underlying co-morbidity was more pronounced in survivors, non-survivors had a slightly higher median APACHE II, higher SOFA score and higher DIC score. However, the number of organ failures was identical in both groups.
Overall hospital mortality rate was similar as observed in the Belgian Registry and 28-day mortality was equal to the results of the PROWESS study. Due to the limited number of patients, it is not clear if patients should be selected based on APACHE II, DIC or number of organ failures. However, selection based on number of organ failures is more appropriate due to intrinsic problems of the APACHE II score.
KeywordsDrotrecogin alpha Drug use evaluation Hospital Intensive Care Mortality Organ failure Severe sepsis Sepsis
Unable to display preview. Download preview PDF.
Conflicts of interest
- 5.Bernard GR, Vincent JL, Laterre PF, LaRosa SP, Dhainaut JF, Lopez-Rodriguez A, et al. Efficacy and safety of recombinant human activated protein C for severe sepsis. Recombinant Human Protein C Worldwide Evaluation in Severe Sepsis (PROWESS) Study Group. N Engl J Med 2001;344:699–706PubMedCrossRefGoogle Scholar
- 6.Vincent J, Laterre P, Janes J, Nelson D, Haentjens T, Sartral M, et al. Analysis of Drotrecogin alfa (activated) use in Belgium: Comparison to PROGRESS Registry Data. Abstract 227 presented at the ESICM, European Society of Intensive Care Medicine, Amsterdam, September, 2005Google Scholar
- 7.Package insert. Xigris (drotrecogin alpha). Eli Lilly, Houten, The Netherlands, January 2005.Google Scholar
- 8.Moniteur Belge - Belgisch Staatsblad nr. 325, Ministerial Decree 21–10–2005: Terugbetaling van Xigris.Google Scholar
- 17.Abraham E, Laterre PF, Garg R, Levy H, Talwar D, Trzaskoma BL, et al. Drotrecogin alfa (activated) for adults with severe sepsis and a low risk of death. Administration of drotrecogin alfa (activated) in early stage severe sepsis (ADDRESS) Study Group. N Engl J Med 2005;353:1332–41PubMedCrossRefGoogle Scholar
- 18.FDA warning surgical patients. Available from http://www.fda.gov/medwatch/SAFETY/2005/xigris_DHCP.pdf. Accessed March 15, 2006.
- 19.Vincent JL, Bernard GR, Beale R, Doig C, Putensen C, Dhainaut JF, et al. Drotrecogin alpha (activated) treatment in severe sepsis from the global open-label trial ENHANCE: further evidence for survival and safety and implications for early treatment. Crit Care Med 2005;33:2266–77PubMedCrossRefGoogle Scholar
- 20.FDA warning pediatrics. Available from http://www.fda. gov/medwatch/SAFETY/2005/Xigris_dearhcp_4-21-05.pdf. Accessed March 15, 2006.
- 21.Pelloquin A, Zimner S, Camps E. Use of Drotrecogin Alpha (Xigris) in Pitie-Salpetriere hospital. Abstract DI-73 presented at the 5th Spring Conference on Clinical Pharmacy, European Society of Clinical Pharmacy, Stockholm, May 25–28, 2005.Google Scholar
- 22.Schlecht D, Dallay S, Bauer S, Ferrandiere M, Grassin J, Antier D. One year analysis of prescriptions of drotrecogin alfa (activated) in medical and surgical intensive care units. Abstract DI-218 presented at the 34th European Symposium on Clinical Pharmacy, European Society of Clinical Pharmacy, Amsterdam, October 26–29, 2005Google Scholar